FDA approves Teva’s expanded indication for Uzedy for bipolar I disorder
UZEDY (risperidone) extended-release injectable suspension for subcutaneous use is indicated for use every one or two months for the treatment of schizophrenia in adults
UZEDY (risperidone) extended-release injectable suspension for subcutaneous use is indicated for use every one or two months for the treatment of schizophrenia in adults
PeptiGlow features premium-grade hydrolyzed collagen peptides that support skin elasticity and hydration
The company plans to use the funds raised from the net proceeds to repay or prepay certain loans
RedHill will receive $500,000 in guaranteed payments, including a $250,000 upfront payment and $250,000 in fixed payments due within 18 months
Medico Remedies receives order worth US$ 1,781,000
Lonza boosts TheraPEAK line with new Cytokines and AAV Medium for next-gen therapies
States exhorted to ensure rational use of cough syrups, particularly among children, as most coughs are self-limiting and do not require pharmacological treatment
Combination reduced the risk of disease progression or death by 46% and risk of death by 27% in pivotal phase III IMforte study
With global certification in place, the Ambernath site expands Supriya’s footprint beyond APIs into high-margin formulations
BPDCN is a challenging blood cancer with characteristics of both leukemia and lymphoma
Subscribe To Our Newsletter & Stay Updated